Jul 4
|
How Much of Your Portfolio Should Be in International Stocks?
|
Jul 3
|
Mercedes to LVMH Are Blunting the EU’s Fight Against Trump’s Tariffs
|
Jul 3
|
Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA
|
Jul 1
|
10 European Dividend Stocks That Could Beat Their U.S. Counterparts
|
Jul 1
|
Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP
|
Jul 1
|
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
|
Jul 1
|
Adagene announces up to $25 million strategic investment from Sanofi
|
Jun 30
|
Sanofi (ENXTPA:SAN) Gains Orphan Drug Status In Japan For CIDP Treatment
|
Jun 30
|
Hedge Fund Strategy Built on Catastrophes Taps Hot New Trend
|
Jun 30
|
ESTEVE to acquire medicine to treat medullary thyroid cancer
|
Jun 30
|
Press release: Availability of the Q2 2025 Aide mémoire
|
Jun 30
|
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
|
Jun 27
|
Kymera’s partnerships with Sanofi and Gilead drive value
|
Jun 26
|
Kymera weakness a buying opportunity, says Stifel
|
Jun 26
|
Morning Movers: General Mills dips following fourth quarter report
|
Jun 26
|
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
|
Jun 26
|
Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts
|
Jun 25
|
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
|
Jun 25
|
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi
|
Jun 25
|
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
|